KOL Insight

Congestive Heart Failure Pulse Survey

The study was just closed early, as LCZ696 increased time to first occurrence of either

cardiovascular death or heart failure hospitalization, though details have not been released.

We surveyed 10 US Cardiologists to get a preview of how they would use LCZ696 under different

assumptions about what the study found.

Dermatology KOL Interview

BioMedTracker – Dermatology KOL Interview                                                                                                                           In recent years, patients have become more comfortable with aesthetic dermatology procedures as they have become more widespread.

2014 October Dermatology Survey

We performed a 5-question survey of 21 dermatologists to gauge usage of drugs and devices for the treatment of common dermatological conditions and for aesthetic procedures.

2015 Breast Cancer Pulse #2

This 5-question pulse of 24 oncologists practicing in the United States focuses on the usage of HER2-targeted agents for the treatment of breast cancer.

2016 Biomedtracker Post-EASL Hepatitis C Survey

We performed a 9-question survey of 29 EU and 31 US hepatologists and gastroenterologists after the European Association of the Study of the Liver (EASL) International Liver Conference (ILC) from April, 2016 in Barcelona to gauge current and projected prescribing practices for hepatitis C virus (HCV) infection.

GLP-1 Pulse Survey

This survey of US primary care physicians (n=10) and endocrinologists (n=10) was undertaken to evaluate the impact of GLP-1 agonists if they were to be introduced in the Diabetes market.

Acute Lymphocytic Leukemia KOL Interview

[Newer treatments] are definitely being used in the relapse population, and that’s where they made their mark like most other investigational agents for other cancers. I think the issue is that the response rate with initial induction therapy is so high. Whether or not there is going to be a maintenance-type study strategy, that’s a question with some of these therapies that are relatively low toxicity, but when you have a complete remission rate of 90-95%, and ALL’s not the most common disease – it’s a pretty rare cancer actually – that it’s going to be difficult to do large studies for indications in the randomized setting.

Datamonitor Schizophrenia KOL Interview 2

KOL believes that the available schizophrenia treatments that provide the most efficacy also have the highest side effects.

Treatment of VTE – US KOL Interview

This interview with a US hematologist focuses on the changing dynamics with the introduction of novel/direct oral anticoagulants (NOAC, DOAC) in the treatment of venous thromboembolism (VTE) and prevention of recurrence.